ArticlePharmaceutics2022

Two-in-One Nanoparticle Formulation to Deliver a Tyrosine Kinase Inhibitor and microRNA for Targeting Metabolic Reprogramming and Mitochondrial Dysfunction in Gastric Cancer.

Yu-Li Lo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.